Prexige® (lumiracoxib), a novel COX-2 selective inhibitor approved in the United Kingdom
Basel, 16 September 2003 - Novartis announced today that Prexige® (lumiracoxib), a novel COX-2 selective inhibitor, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Prexige® was approved for the symptomatic relief of osteoarthritis (OA) at 100-200mg daily. In addition, Prexige® 400mg daily has been approved for the short-term relief of moderate to severe acute pain associated with primary dysmenorrhea, dental surgery and orthopaedic surgery.
Please find full press release under the following link:
